Earnings Preview: Eli Lilly (LLY) Q2 2026

Report Date: Wednesday, August 5, 2026 (Before Market Open)
Consensus EPS: $6.58
Market Cap: $994.9B
Stock Price: $1,115.68 (prior close, -0.51%)

The Setup

Eli Lilly reports Q2 results Wednesday morning with massive expectations baked in. The stock trades at a $1T valuation driven entirely by GLP-1 drug dominance (Mounjaro for diabetes, Zepbound for obesity). Street expects another blowout quarter, but supply constraints and Novo Nordisk competition keep risk/reward asymmetric.

Key Question: Can LLY deliver the revenue acceleration needed to justify a 67x forward P/E?

What to Watch

1. GLP-1 Revenue (Mounjaro + Zepbound)

Why it matters: These two drugs are the entire thesis. Q1 2026 saw $5.2B combined sales (+35% QoQ). Street models $6.5-7B for Q2.

Bull case:

Bear case:

Watch for: Guidance raise on FY26 GLP-1 sales. Anything below $28B total year = disappointment.

2. Supply Expansion Timeline

The bottleneck: LLY has acknowledged demand far exceeds supply. New Indiana manufacturing plant came online Q1, but ramp takes quarters.

What management needs to say:

Competitor context: Novo Nordisk also supply-constrained, but if they solve it first, LLY loses share.

3. Pricing & Reimbursement

Risk: Medicare Part D negotiation list (Aug 2026) may include Mounjaro. If price cuts mandated, margins compress.

Insurer pushback: Commercial payers (UnitedHealth, Cigna, Aetna) restricting GLP-1 coverage due to cost. LLY needs to prove real-world cost savings (reduced heart attacks, hospitalizations) to maintain access.

Watch for: Comments on “net pricing trends” — if gross-to-net deductions widen, it’s a warning sign.

4. Pipeline Updates

Beyond GLP-1:

Why it matters: LLY needs growth drivers beyond Mounjaro/Zepbound to sustain $1T valuation long-term.

Bull Case

✅ GLP-1 demand is structural, not a fad. Obesity epidemic + proven cardiovascular benefits = decades-long tailwind.
✅ Supply coming online = revenue inflection. LLY has the manufacturing edge vs. NVO.
✅ Pipeline depth. Donanemab (Alzheimer’s), orforglipron (oral GLP-1), retatrutide (next-gen GLP-1) = multiple shots on goal.
✅ Pricing power. Despite insurer pushback, GLP-1 drugs reduce long-term healthcare costs → defensible pricing.

Target: Street sees $1,300-1,400 if Q2 confirms supply ramp + pipeline hits.

Bear Case

⚠️ Valuation stretched. 67x forward P/E leaves zero room for error. Any guidance miss = -10% correction.
⚠️ Competition heating up. Novo Nordisk, Amgen, Pfizer all launching competing GLP-1s in 2026-27.
⚠️ Medicare pricing risk. IRA drug negotiation could cut Mounjaro price 40-60% for Medicare population (33M people).
⚠️ Supply still capped. If LLY can’t meet demand by year-end, NVO captures share permanently.
⚠️ Macro headwind. Consumer spending weakening (April Liberation Day tariffs still pressuring discretionary) → elective obesity drug use may decline.

Downside: $950-1,000 if supply disappoints or Medicare pricing announced.

Technicals

Support: $1,050 (50-day MA)
Resistance: $1,180 (all-time high)
RSI: 52 (neutral)
Volume: Below average past week — low conviction either way

Chart setup: Consolidating after April-May rally. Needs earnings beat + raise to break out. Miss = retest of $1,000.

The Trade

Conservative: Wait for the print. Valuation doesn’t leave margin for error.

Aggressive long: Buy $1,100 calls (1-2 weeks out) betting on supply ramp confirmation + guidance raise. Risk: total loss if supply still constrained.

Hedge: Long LLY / Short NVO pair trade if you believe LLY’s supply advantage is real.

Bottom Line

📊 LLY is priced for perfection. GLP-1 revenue must accelerate, supply must ramp, and pipeline must deliver. One miss = -10%. Big beat + raise = $1,300+. Most likely: in-line beat, modest raise, stock flat. Not a clear risk/reward at $1,115. Better entry if it pulls back to $1,050 post-earnings or if supply commentary is unambiguously bullish.

Positioning: Neutral. Wait for the report.

Preview published: 2026-08-05 13:30 UTC
Earnings call: Wed, Aug 5, 2026 BMO